Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

Date Founded



222 Berkeley Street, 12th Floor, Boston, MA, 02116, USA

Type of Company


Employees (Worldwide)




Company Description

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Contact Data
Trying to get in touch with decision makers at Rhythm Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Interim President & Chief Executive Officer

Chief Commercial Officer

Chief Medical Officer

Chief Human Resources Officer

Head-Investor Relations & Corporate Communications

Vice President, Translational R&D & Alliances

Board of Directors

President, Chief Executive Officer & Director at KSQ Therapeutics, Inc.

Executive Vice President & Chief Commercial Officer at Vertex Pharmaceuticals, Inc.

Executive Officer, Director at Adolor Corp.

Managing Director at MPM Asset Management LLC

General Partner, Washington DC at New Enterprise Associates

Co-Founder, President & Chief Executive Officer at Trevi Therapeutics, Inc.

Senior Advisor at JSB-Partners LP

Paths to Rhythm Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
Rhythm Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Details Hidden
Recent Transactions
Details Hidden

Rhythm Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Rhythm Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Rhythm Pharmaceuticals, Inc. raised money in a private placement transaction

Transaction Advisors

Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock


Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock


Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock


Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants

Chairman of the Board, Chief Executive Officer at Allergan GI Corp.

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Five Year Compounded Annual Growth Rate Of Revenue
Non-Profit Donations & Grants
$5,000 - $10K
Details Hidden

Pfizer Venture Investments focuses on investments in emerging companies that are developing or compounding technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry. The firm focuses on healthcare related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT, and other technologies impacting drug discovery and development.Pfizer Venture Investments may invest up to $10 million per round in selected companies at any stage of development including start-ups, spinouts and consortia investments with emphasis on growth stage opportunities. Other investments, including fund investing, spinout opportunities and PIPEs are also be considered as appropriate. They have the ability to lead or join a syndicate of investors and they take seat on the board of directors.

Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

MPM invests in companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. The firm portfolio companies aims to revolutionize the face of medicine across multiple areas including cancer, diabetes, obesity, pain, eHealth and more. With their experienced and dedicated team of operating executives and medical and scientific advisory board they are powering novel medical breakthroughs that transform patient lives.

Ipsen SA Pharmaceuticals | Boulogne-billancourt, France

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Camurus AB Wholesale: Consumer Non-Durables/Sundries | Lund, Sweden

Camurus AB is a research-based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Recipharm AB Medical Support Services | Jordbro, Sweden

Recipharm AB engages in the manufacture of pharmaceuticals and contract development services for pharmaceutical companies. It operates through the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment produces products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and is headquartered in Stockholm, Sweden.

Millendo Therapeutics, Inc. Pharmaceuticals - Ann Arbor, MI

Millendo Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in the development of novel treatments for endocrine diseases. Its products include livoletide and nevanimibe. The company was founded in April, 2011 and is headquartered in Ann Arbor, MI.

Soleno Therapeutics, Inc. Pharmaceuticals - Redwood City, CA

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Saniona AB Biotechnology - Ballerup, Dnk

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. Its research focuses on ion channels, which makes up of protein that enables and controls the passage of charged ions across cell membranes. It operates through the following segments: Tesofensine; Tesomet; NS2359; CAD-1883; SAN711; Boehringer Ingelheim program; IK program; BenevolentAI program; and Nicotinic a6 program, Kv7 program; and Cadent Therapeutic program. The company was founded by Claus Tycho Bræstrup, Anker Gunvald Lundemose, Jørgen Drejer, Palle Christophersen, and Thomas Feldthus in 2011 and is headquartered Ballerup, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Rhythm Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Rhythm Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Rhythm Pharmaceuticals, Inc..